跳至主要内容
临床试验/NCT05810922
NCT05810922已完成不适用

Arbutus Berry - Intervention Study to Evaluate the Modulation of Intestinal Microbiota and Metabolic Parameters

Universidade Nova de Lisboa2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年11月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
2
主要终点
Changes in gut microbiota characterization

研究概览

简要总结

The tree that produces the arbutus berry, the strawberry tree, scientific name Arbutus unedo L., belongs to the family of Ericaceae. It exists in almost all of Southern Europe in arid and siliceous lands, in woods and forests and is very common in Portugal.

Known for its use in the production of liqueurs and brandy, the arbutus berry is a fruit that can be consumed in nature or incorporated in the preparation of other foods. Arbutus berry has been attributed some properties beneficial to health given its low caloric value and its high content of vitamin C and flavonoids, which is why it is considered a good source of antioxidants.

Arbutus has a high carbohydrate content (70-80% dry weight) with a relevant fiber fraction (10-30%), constituting an interesting source of vegetable protein (1-9%) and lipids (2-3%). Given this interesting nutritional composition, the hypothesis is that a daily consumption of this fruit can have an impact in health outcomes such as microbiota modulation and an improvement of metabolic parameters.

详细描述

The main objective of this clinical trial is to evaluate the effect of including a daily consumption of arbutus berry on the composition and diversity of the intestinal microbiota. It is also intended to evaluate metabolic parameters to determine the impact of this intervention.

Participants will consume 50g or 200g of arbutus berry daily for 4 weeks. This study aims to provide scientific evidence regarding the impact of arbutus berry consumption on intestinal microbiota and general health improvements.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Caucasian.
  • Age between 18 and 50 years.
  • Filling informed consent.
  • Body mass index (BMI) between 18,5 kg/m2 and 25 kg/m2.

排除标准

  • Arbutus berry sensibility.
  • Arbutus berry daily consumption in the month before the study begin.
  • Having taken antibiotics within the 6 months prior to beginning the study.
  • Use of pro/prebiotics or fiber as a dietary supplement or any food/molecule that modifies intestinal transit time 6 weeks before recruitment.
  • Use of laxative 6 weeks before recruitment.
  • Specific nutritional therapy (e.g. high protein).
  • Excessive alcohol consumption.
  • Diagnosis of gastrointestinal pathology, hormonal or thyroid pathology, autoimmune diseases, chronic use of corticosteroids, psychiatric disease or Diabetes Mellitus.
  • Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins.
  • Pregnant or breastfeeding.
  • Participation in another clinical trial within the last 3 months.

结局指标

主要结局

Changes in gut microbiota characterization

时间窗: 14 days

Difference in gut microbiota taxonomic characterization, from baseline to the end of intervention

Changes in gut microbiota diversity

时间窗: 14 days

Difference in gut microbiota Shannon index, from baseline to the end of intervention

次要结局

  • Changes in IL-6(14 days)
  • Changes in HDL cholesterol(14 days)
  • Changes in adiponectin(14 days)
  • Changes in short chain fatty acids amount in the stool(14 days)
  • Changes in leptin(14 days)
  • Changes in alkaline phosphatase activity in the stool(14 days)
  • Changes in total cholesterol(14 days)
  • Changes in triglycerides(14 days)
  • Changes in fasting glucose(14 days)
  • Changes in HOMA-IR(14 days)
  • Changes in LDL cholesterol(14 days)
  • Changes in high sensitivity PCR(14 days)
  • Changes in TNFa(14 days)
  • Changes in IL-10(14 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验